| 000 | 02673nam a22003495i 4500 | ||
|---|---|---|---|
| 001 | 75992 | ||
| 003 | ES-MaUEC | ||
| 005 | 20240119142142.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130804s2013 xxu| s |||| 0|eng d | ||
| 020 | _a9781461476542 | ||
| 040 | _aES-MaUEC | ||
| 050 | 4 |
_aRC271.C5 _bR47 2013 EB |
|
| 245 | 0 | 0 |
_aResistance to Immunotherapeutic Antibodies in Cancer : _bStrategies to Overcome Resistance _cedited by Benjamin Bonavida |
| 260 |
_aNew York _bSpringer International Publishing _c2013 |
||
| 300 | _a1 recurso en línea (XIII, 202 p.) 29 il., 15 il. col. | ||
| 336 |
_aTexto (visual) _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 490 | 1 |
_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v2 |
|
| 520 | _aThe current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance. Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs. | ||
| 942 |
_2lcc _cLE |
||
| 988 | _aEBOOK, EBSPRINGERrevisado | ||
| 650 | 4 |
_aCáncer _xQuimioterapia _0comprobar BNE19951018561 _9674463 |
|
| 700 | 1 |
_aBonavida, Benjamin _eeditor literario _984738 _0Local |
|
| 830 | 0 |
_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v2 _9133185 _0Local |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-7654-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 901 | _ai9781461476542 | ||
| 907 |
_a.b12816103 _b10-10-17 _c01-10-14 |
||
| 998 |
_am _a_alco _a_vill _b10-03-17 _cm _dz _ef _feng _gxxu _h0 |
||
| 945 |
_aRC271.C5 R47 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545483 _z06-04-17 |
||
| 999 |
_c75992 _d75992 _x1 |
||